INTRODUCTION
============

In 1992, safe and effective vaccines for prevention of hepatitis A were licensed in a number of countries.^[@r01]^ Use of hepatitis A vaccine in several countries, including the United States, Israel, and Argentina, has led to a dramatic decrease in reported rates of hepatitis A.^[@r02]^ In 1988, the largest hepatitis A outbreak in the world (more than 310 000 cases) occurred in Shanghai, China. It heightened public concern^[@r03]^ and illustrated how accumulation of susceptible individuals after a decrease in transmission could result in large outbreaks of disease in the absence of vaccination-induced population immunity. In 1992, the world's first live attenuated liquid hepatitis A vaccine was licensed in China.^[@r04]^ Beginning in 2000, a freeze-dried, more heat-stable, preparation progressively replaced the liquid form. In 2002, the first Chinese inactivated hepatitis A vaccine was licensed. The incidence of hepatitis A has decreased in all age groups, likely due to changing socioeconomic conditions and increasing hepatitis A vaccine use.^[@r04]^

In 2007, hepatitis A vaccine was fully integrated into the Chinese national immunization program and is provided free to all children older than 18 months. The Chinese national immunization program uses both the live attenuated vaccine (1 dose, subcutaneous route, about half of the market share) and the inactivated vaccine (2 doses, 6 months apart, about half of the market share). H2 strain vaccines have subsequently been licensed in India (2005), Guatemala (2006), the Philippines (2008), and Thailand (2010). The Chinese experience in developing and using the hepatitis A vaccine has not been widely shared, since most studies have been published in Chinese.

LITERATURE REVIEW AND SURVEILLANCE
==================================

Definitions
-----------

Immunogenicity, efficacy, and adverse events after immunization (AEFIs) were defined according to the recommendations of the World Health Organization and relevant position papers, consistent with common use in the published literature.^[@r05]--[@r08]^ Immunogenicity was defined as the ability of a hepatitis A vaccine to elicit an immune response of at least 20 mIU/mL. Efficacy was defined as a reduction in the incidence of a disease among people who have received a vaccine versus those who have not. An AEFI was defined as a post-immunization medical event that causes concern and is believed to be caused by the immunization.

Literature review
-----------------

We searched Chinese-language scientific journals and international journals using the key words: "hepatitis A", "vaccine", "immunogenicity", and "safety". To be included in the present review, the study must have (1) been an investigation of a vaccine produced in China, (2) included a control group, (3) included a denominator, nominator, or ratio that could be used to calculate rates, (4) described the duration time of follow up, rate of seroconversion, and geometric mean titer (GMT), and (5) been published between 1992 and 2010. We also reviewed official licensure documents and policy decisions regarding the use of hepatitis A vaccine in China.

Surveillance data analysis
--------------------------

### Data from the national AEFI surveillance system

In 2005, the China Centers for Disease Control (CDC) established the National AEFI Surveillance System on the basis of WHO guidelines.^[@r08]^ This system is a computer-based real-time system through which vaccination stations, clinics, manufacturers, parents, and the general public can report suspected AEFIs to county CDCs.

DESCRIPTION OF VACCINES
=======================

Overview of hepatitis A vaccines produced in China
--------------------------------------------------

In 1992, the first live attenuated hepatitis A vaccine was licensed. Chinese manufacturers currently produce live attenuated hepatitis A vaccine using the H2 strain (since 1992) and LA-1 strain (since 1994). In 2002, the first inactivated hepatitis A vaccine, similar in concept to those used internationally, was licensed in China. By 2010, there were 3 inactivated hepatitis A vaccines available in China: the LV-8 and TZ 84 strains and a Vero cell-based strain.^[@r09]^

### H2 strain attenuated hepatitis A vaccines

*Development and licensure:* An attenuated live hepatitis A vaccine (H2 strain) was derived from a patient fecal specimen isolated in Hangzhou, China in the early 1980s. After isolation and passage in a culture of newborn monkey kidney cells, adaptation to growth in human lung diploid cells (KMB17), and serial passage at low temperature (32°C) in KMB17 cells, this strain became the master seed virus for the H2 strain vaccine.^[@r10]^ Two manufacturers used this H2 strain in a liquid preparation. In 2000, a freeze-dried preparation was licensed and replaced the liquid preparation. Both used the same H2 strain after cell culture, harvest, purification, and addition of a stabilizer (Table [1](#tbl01){ref-type="table"}).

###### Monovalent hepatitis A vaccines developed and produced in China

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type                              Trade name    Attenuated\   Year licensed   Adjuvant     HAV antigen\             Manufacturers                                             
                                                  HAV strain                                 dose/injection                                                                     
  --------------------------------- ------------- ------------- --------------- ------------ ------------------------ ------------------------- ------------------------------- ------------------------
  Live-attenuated\                  Weisairuiji   H2            1992            2003         None                     1.0 mL\                   Institute of Medical Biology\   
  (initially in liquid form, now\                                                                                     (6.50 lg CCID~50~)        of the Chinese Academy of\      
  freeze-dried; the liquid\                                                                                                                     Medical Sciences; Kunming       
  form was removed from\                                                                                                                                                        
  the market because the\                                                                                                                                                       
  freeze-dried preparation is\                                                                                                                                                  
  more stable)                                                                                                                                                                  

                                                                                                                                                                                

  Freeze-dried\                     H2            1992          2003            None         0.5 mL\                  1 mL\                     Zhejiang Pukang\                
  live\                                                                                      (6.50 lg CCID~50~)       (6.50 lg CCID~50~)        Biotechnology Company\          
  attenuated\                                                                                                                                   Limited, Zhejiang Academy\      
  hepatitis A\                                                                                                                                  of Medical Sciences,\           
  vaccine                                                                                                                                       Hangzhou                        

                                                                                                                                                                                

  Hepatitis A\                      LA-1          1997          2000            None         1.0 mL\                  Changchun Institute of\                                   
  (live) vaccine,\                                                                           (6.50 lg CCID~50~)       Biological Products\                                      
  freeze dried                                                                                                        & Changchun Changsheng\                                   
                                                                                                                      Life Sciences Limited                                     

                                                                                                                                                                                

  HAVAC                             LA-1          1997          2000            None         1.0 mL\                  Changchun Institute of\                                   
                                                                                             (6.50 lg CCID~50~)       Biological Products                                       

                                                                                                                                                                                

  Inactivated                       Healive       TZ84          2002            N/A          Aluminium\               250 units                 500 units                       Sinovac Biotech Co Ltd
                                                                                             hydroxide                                                                          

                                                                                                                                                                                

  Weisairuian                       Lv-8          2006          N/A             Aluminium\   320 ELISA units          640 ELISA units           Institute of Medical Biology\   
                                                                                hydroxide                                                       of the Chinese Academy of\      
                                                                                                                                                Medical Sciences; Kunming       

                                                                                                                                                                                

  Veraxim                           YN5           2009          N/A             Aluminium\   800 ELISA units/0.5 mL   1600 ELISA\               Shanghai Wison\                 
                                                                                hydroxide                             units/1 mL                Bioengineering Inc              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*not available at present.

*Production and quality assurance:* The freeze-dried, live attenuated hepatitis A vaccine is made with the H2 strain and KMB17 cell substrate and includes a protective additive that is patented in China. The vaccine comes in a 0.5-mL vial (for children) and a 1.0-mL vial (for adults) (Table [1](#tbl01){ref-type="table"}). Administration is subcutaneous and shelf life is 18 months. During preparation, every master seed lot and working seed lot must pass a security test on monkeys, in accordance with China State Food and Drug Administration (SFDA) requirements. The KMB17 cell substrate is made of human embryonic lung diploid cells obtained from the Institute of Bio-Medical Sciences, Chinese Academy of Medical Sciences. In 2006, Good Manufacturing Practices (GMP) certificates were reissued for the 2 manufacturers. Between 2006 and 2009, the SFDA released 111 lots (about 9.85 million doses) of H2 strain vaccine.

### LA-1 live attenuated hepatitis A vaccine

*Development and licensure:* In 1985, the virus precursor to the LA-1 strain was isolated from the stool of a 2-year-old boy with hepatitis in Heilongjiang Province, China.^[@r11]^ The Shanghai CDC and Changchun Institute of Biological Products collaborated to develop this into an attenuated strain.^[@r11]^ The China SFDA licensed a liquid form of the vaccine in 1997. In 2000, a freeze-dried preparation of the vaccine received a new drug license and marketing authorization and, in 2001, it was authorized for large-scale production, to replace the liquid form of the vaccine.

*Production and quality assurance:* Two manufacturers produce hepatitis A vaccine based on the LA-1 strain. The freeze dried live attenuated hepatitis A vaccine is made with the LA-1 strain and the 2BS cell substrate,^[@r12]^ which consists of human embryonic lung diploid cells (2BS) obtained from the national vaccine and serum institute. A patented protective additive includes trehalose, sodium glutamate, arginine, and dextran. The LA-1 vaccine comes in a 1.0-mL vial for subcutaneous administration and has a shelf life of 18 months. During preparation, every master seed lot and working seed lot must pass a security test on monkeys.^[@r12]^ In 2008, the GMP certificate was reissued. Between 2006 and 2009, SFDA released 164 lots (about 16 million doses of LA-1 strain vaccine).

### Inactivated hepatitis vaccines

*Development and licensure:* In 2002, a domestically produced inactivated hepatitis A vaccine was licensed in China.^[@r13]^ This vaccine was prepared from the TZ84 strain derived from a fecal specimen of a patient who developed hepatitis A in Tangshan, Hebei Province in 1985. The virus used for vaccine production grew in human embryonic lung diploid fibroblast 2BS cells. Whole virus is extracted from tissue culture, purified, inactivated with formalin, and then adsorbed onto aluminium hydroxide. Sinovac Biotech Co Ltd developed and manufactures the TZ84 inactivated hepatitis A vaccine. In 2006, another domestic inactivated vaccine was licensed. The vaccine is prepared from the Lv-8 strain derived from the stool specimen of a 1988 patient from Shanghai. The strain was cultured in 25 passages, cultured in KMB17 cells for 12 days, harvested, purified, inactivated, and then adsorbed into aluminium hydroxide.^[@r14]^

*Production and quality assurance:* The steps involved in the manufacture of inactivated hepatitis A vaccine are similar to those for live attenuated vaccine. However, after extraction, there is an additional purification and inactivation step before the bulk vaccine is prepared.^[@r15]^ In 2008, the GMP certificate for the TZ84 vaccine was reissued. Between 2002 and 2009, the SFDA released 195 lots (more than 28 million doses of the TZ84 strain). Production of the Lv-8 strain is identical to that of the TZ84 strain, but the production period is shorter, which potentially increases production capacity^[@r16]^ (Table [1](#tbl01){ref-type="table"}). In addition, the inactivated hepatitis A vaccine Veraxim (Vero cell) was licensed in China in 2009.

Clinical trials
---------------

### Safety of live attenuated hepatitis A vaccines

*Safety among recipients:* Initial clinical trials of live attenuated hepatitis A vaccines reported AEFIs including systemic fever (0.4% to 5%)^[@r17]^ and local rash (0% to 1.1%).^[@r18]^ Studies conducted between 1998 and 2003 described outcomes from a total of 589 940 recipients of live attenuated hepatitis A vaccines. Of the 3031 recipients of the H2 vaccine, 7 (0.23%) developed elevated aminotransferases and 2 (0.015%) developed other, minor symptoms.^[@r19]^

*Horizontal transmission:* Two studies^[@r20],[@r21]^ examined the potential for horizontal transmission of live attenuated hepatitis A vaccine (H2) among a total of 42 vaccinated individuals and 75 contacts. One study investigated 38 recipients of the (H2 strain) vaccine. Virus was isolated from the stools of 34 recipients. Among the 75 contacts, 53 (71%) developed infection with vaccine virus isolated from the stools. Among the 42 recipients, none had an alanine aminotransferase level greater than 40 U/L; however, the overall mean alanine aminotransferase level increased from 12.84 U/L before vaccination to 16.49 U/L after vaccinated (*P* \< 0.05).^[@r20]^ Two HAV-positive stools were isolated from recipients and 2 contacts and were injected into 8 monkeys. Six monkeys subsequently tested positive for vaccine virus in stool specimens; none developed abnormalities. Another study investigated 4 recipients of the H2 strain vaccine, and vaccine virus was isolated from 3 stools.^[@r21]^

Safety of inactivated hepatitis A vaccines
------------------------------------------

*Safety among recipients:* Initial clinical trials of inactivated hepatitis A vaccines reported AEFIs, including systemic fever (1% to 8%). A review of the literature found no evidence of local rash or injection site induration.^[@r22]^ The types and rates of local and systemic reactions were similar after primary and booster doses, and no serious adverse reactions were noted.^[@r23]^ The domestic inactivated hepatitis A vaccine was also safe among recipients with liver disease.^[@r24]^ Passive surveillance data suggest that the incidences of AEFIs were similar to those of the live attenuated vaccine in China.^[@r25]^

Immunogenicity
--------------

*Live attenuated vaccine:* With respect to the H2 vaccine, the median seroconversion rate for single doses greater than or equal to 6.5 log cell culture infectious doses (CCID) was 94% (range, 74%--100%) after 2 months and 91% (56%--100%) after 6 months. The GMT of anti-HAV antibody of initially susceptible subjects was 41 to 1607 mIU after 2 months, 75 to 119 mIU at 3 months, and 42 to 1945 mIU at 6 months. Overall, seroconversion rates were highest (median, 88%; range, 56%--100%) at 3 to 6 months after vaccination and were lower (median, 74%; range, 10%--100%) at 12 months. One study reported that antibodies persisted among 72% to 88% of individuals 15 years after 1 dose.^[@r26],[@r27]^ Administration of a second dose of vaccine after 6 months led to seroconversion rates of 100% and higher GMTs.^[@r28]^ After a booster dose of H2 live attenuated vaccines, 100% of vaccine recipients seroconverted.^[@r29]^

For the LA-1 vaccine, the median seroconversion rate for doses greater than or equal to 6.5 log CCID was 78% (range, 74%--87%) at 3 months and 83% (83%--83%) at 6 months. The GMT of anti-HAV antibody among initially susceptible individuals was 90 to 122 mIU at 3 months and 80 mIU at 6 months, as reported in 3 studies.^[@r30]--[@r32]^ One study reported that antibodies persisted among 99% of individuals (71%--100%) at 3 years.^[@r33]^ In addition, an Indian study reported that freeze-dried live attenuated hepatitis A vaccine had good immunogenicity at 6 weeks (95.1% seroconversion) and 6 months (97.9% seroconversion)^[@r34]^ (Table [2](#tbl02){ref-type="table"}).

###### Studies of immunogenicity of live attenuated hepatitis A vaccines produced in China, 1997--2009

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Vaccine\   Subjects\   Duration of follow up after first dose\   GMT\              Seroconversion,\   Dosage\           Number of doses received\   Age group\
                           used       (No.)       (months)                                  (mIU)             %                  CCID~50~/mL       (schedule in months)        (years)
  ------------------------ ---------- ----------- ----------------------------------------- ----------------- ------------------ ----------------- --------------------------- ------------
  Zhang Y, 1997^[@r43]^    H~2~       45          2.5                                       266               98                 1.8 mL 10^6.83^   1                           5--7

  52                       2.5        102         90                                        0.9 mL 10^6.52^   1                                                                

  39                       2.5        81          80                                        0.4 mL 10^6.17^   1                                                                

  59                       2.5        188         92                                        0.9 mL 10^6.52^   1                  18--22                                        

                                                                                                                                                                               

  Xu Z, 1998^[@r30]^       H~2~       102         3                                         87                92                 10^7.0^           1                           1--9

  101                      6          91          87                                        1                                                                                  

                                                                                                                                                                               

  LA-1                     118        3           119                                       74                10^6.75^           1                                             

  95                       6          81          83                                        1                                                                                  

                                                                                                                                                                               

  Xu Z, 1999^[@r31]^       H~2~       102         3                                         87                92                 10^7.0^           1                           1--9

  101                      6          123         74                                        1                                                                                  

                                                                                                                                                                               

  LA-1                     119        3           91                                        87                10^6.75^           1                                             

  95                       6          81          83                                        1                                                                                  

                                                                                                                                                                               

  Gong J, 1999^[@r32]^     LA-1       119         3                                         123               74                 10^6.75^          1                           1.5--10

  95                       6          801         83                                        1                                                                                  

  60                       12         84          82                                        1                                                                                  

                                                                                                                                                                               

  Wang X, 2001^[@r44]^     H~2~       47          3                                         75                92                 10^6.52^          1                           6--8

  45                       12         26          42                                        1                                                                                  

  46                       24         16          22                                        1                                                                                  

  41                       36         14          17                                        1                                                                                  

  42                       48         12          10                                        1                                                                                  

                                                                                                                                                                               

  Zhang X, 2002^[@r45]^    H~2~       69          0.5                                       49                80                 10^6.5^           1                           4--6

  66                       2          55          83                                        1                                                                                  

  68                       6          80          92                                        1                                                                                  

  68                       9          65          88                                        1                                                                                  

  38                       12         83          92                                        1                                                                                  

  57                       24         134         95                                        1                                                                                  

                                                                                                                                                                               

  42                       0.5        31          60                                        10^6.5^           1                  13--18                                        

  42                       2          41          74                                        1                                                                                  

  39                       6          42          85                                        1                                                                                  

  39                       9          489         87                                        1                                                                                  

  37                       24         33          78                                        1                                                                                  

                                                                                                                                                                               

  Zhuang F, 2003^[@r17]^   H~2~       94          2                                         1607              100                10^6.77^          1                           7--12

  91                       13         495         98                                        1                                                                                  

  95                       24         448         99                                        1                                                                                  

                                                                                                                                                                               

  H~2~                     114        2           1530                                      99                10^6.50^           1                 3--6                        

  111                      13         443         100                                       1                                                                                  

                                                                                                                                                                               

  Huang G, 2003^[@r46]^    H~2~       100         1                                         521               75                 10^6.50^          1                           6--12

  94                       2          1607        100                                       1                                                                                  

                                                                                                                                                                               

  Xu G, 2003^[@r18]^       H~2~       68          2                                         228               91                 10^6.5^           1                           9--10

                                                                                                                                                                               

  Wang X, 2004^[@r28]^     H~2~       26          1                                         19                31                 10^5.5^           1                           3--11

  26                       6          47          58                                        1                                                                                  

                                                                                                                                                                               

  26                       1          1306        100                                       10^5.5^\          1                                                                
                                                                                            and 10^6.83^                                                                       

  26                       6          448         100                                       1                                                                                  

  26                       18         218         92                                        2 (0,6)                                                                            

                                                                                                                                                                               

  Zhuang F, 2005^[@r47]^   H~2~       220         2                                         287               99                 10^6.5^           1                           1--15

  219                      12         226         94                                        1                                                                                  

  176                      72         173         83                                        1                                                                                  

  155                      120        145         80                                        1                                                                                  

                                                                                                                                                                               

  Faridi M, 2008^[@r34]^   H~2~       316         1.5                                       78                68                 10^6.5^           1                           1--5

  279                      6          144         99                                        1                                                                                  

                                                                                                                                                                               

  Xu G, 2008^[@r48]^       H~2~       119         2                                         132               94                 10^6.5^           1                           2

  86                       42         179         93                                        1                                                                                  

                                                                                                                                                                               

  Liu H, 2009^[@r49]^      H~2~       40          1                                         55                48                 10^5.5^\          1                           3--13
                                                                                                                                 and 10^6.83^                                  

  37                       6          83          62                                        1                                                                                  

  37                       7          1316        100                                       2 (0,6)                                                                            

  40                       12         451         100                                       2 (0,6)                                                                            

  38                       13         1945        100                                       3 (0,6,12)                                                                         

  33                       24         899         100                                       3 (0,6,12)                                                                         

  40                       84         337         100                                       3 (0,6,12)                                                                         

                                                                                                                                                                               

  43                       1          47          33                                        10^5.5^\          1                                                                
                                                                                            and 10^6.83^                                                                       

  43                       6          72          56                                        1                                                                                  

  44                       7          1586        100                                       2 (0,6)                                                                            

  45                       12         477         100                                       2 (0,6)                                                                            

  41                       24         256         100                                       2 (0,6)                                                                            

  43                       84         85          100                                       2 (0,6)                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CCID: cell culture infective dose 50%.

*Inactivated vaccine:* Studies of the immunogenicity of TZ84 vaccine at recommended doses for children and adults indicated that the median seroconversion rate was 87% (range, 62%--100%) at 1 month after a first dose and that GMT was 28 to 3630 mIU/mL. One month after administration of a booster dose, the seroconversion rate was 100% in 5 studies (GMT range, 264 to 21 696 mIU/mL) (Table [3](#tbl03){ref-type="table"}). A double-blind randomized controlled trial compared TZ84 and a Glaxo Smith Kline (GSK) inactivated hepatitis A vaccine in healthy volunteers aged 1 to 8 years. Four hundred people were assigned to 4 groups. Each participant received 2 doses (at 0 and 6 months) of 1 of the 3 lots of TZ84 vaccine or the GSK vaccine. The seroconversion rate was 100% in all 4 groups at the end of the schedule. GMT ranged from 3237 to 3814 mIU/mL, and there were no significant differences between groups.^[@r09],[@r13]^

###### Studies of immunogenicity of inactivated hepatitis A vaccines produced in China (TZ84)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                   Subjects\   Duration of follow up after first dose\   Mean GMT   Seroconversion, %   Dosage      Number of doses received\   Age group\
                          (No.)       (months)                                                                             (months)                    (year)
  ----------------------- ----------- ----------------------------------------- ---------- ------------------- ----------- --------------------------- --------------------------
  Ren A, 2001^[@r50]^     16          1                                         139        94                  1000 U      1                           18--21

  16                      3           138                                       100        1000 U              1                                       

  16                      7           1067                                      100        1000 U              2 (0,6)                                 

                                                                                                                                                       

  Ren Y, 2002^[@r51]^     63          1                                         182        86                  500 U       1                           1--4

  3                       243         89                                        500 U      1                                                           

  6                       280         84                                        500 U      1                                                           

                                                                                                                                                       

  37                      7           4683                                      100        500 U               2 (0,6)                                 

  26                      7           2718                                      100        500 U               2 (0,6)                                 

                                                                                                                                                       

  Liu C, 2002^[@r52]^     32          1                                         174        94                  1000 U      1                           5--15

  75                      5           5160                                      100        1000 U              2 (0,3)                                 

  55                      7           7540                                      100        1000 U              2 (0,6)                                 

  32                      1           146                                       91         500 U               1                                       

  57                      5           3269                                      100        500 U               2 (0,3)                                 

  50                      5           4535                                      100        500 U               2 (0,3)                                 

                                                                                                                                                       

  Ren Y, 2002^[@r53]^     32          1                                         342        63                  125 U       1                           4--10

  33                      1           382                                       94         250 U               1                                       

  33                      1           391                                       100        250 U               1                                       

  32                      6           531                                       100        125 U               2 (0,1)                                 

  32                      7           3170                                      100        125 U               3 (0,1,6)                               

  33                      7           5963                                      100        250 U               2 (0,6)                                 

                                                                                                                                                       

  Ren A, 2002^[@r23]^     32          1                                         175        88                  1000 U      1                           18--20

  31                      6           264                                       97         1000 U              1                                       

  32                      7           2747                                      100        1000 U              2 (0,6)                                 

  40                      1           159                                       70         500 U               1                                       

  26                      6           259                                       65         500 U               1                                       

  40                      7           1657                                      100        500 U               2 (0,6)                                 

                                                                                                                                                       

  Ren Y, 2003^[@r54]^     39          1                                         371        97                  500 U       1                           5--15

  49                      1           320                                       100        500 U               1                                       

  70                      1           321                                       99         500 U               1                                       

  33                      1           355                                       97         250 U               1                                       

  38                      1           195                                       95         250 U               1                                       

  67                      1           251                                       96         250 U               1                                       

  31                      5           6611                                      100        250 U               2 (0,3)                                 

  36                      5           7154                                      100        250 U               2 (0,3)                                 

  39                      3           2800                                      100        250 U               2 (0,1)                                 

  34                      5           3265                                      100        250 U               2 (0,3)                                 

  33                      7           5963                                      100        250 U               2 (0,6)                                 

  33                      3           1973                                      100        250 U               2 (0,1)                                 

                                                                                                                                                       

  Ren Y, 2003^[@r54]^     34          3                                         417        100                 250 U       1                           5--10

  33                      6           391                                       100        250 U               1                                       

  36                      12          361                                       100        250 U               1                                       

  33                      3           1973                                      100        250 U               2 (0,1)                                 

  34                      5           3265                                      100        250 U               2 (0,3)                                 

  33                      7           5963                                      100        250 U               2 (0,6)                                 

  36                      7           14 893                                    100        250 U               2 (0,12)                                

                                                                                                                                                       

  Ren Y, 2003^[@r54]^     36          13                                        195        94                  250 U       1                           4--10

  36                      12          360                                       100        250 U               1                                       

  49                      1           370                                       100        500 U               1                                       

  49                      12          456                                       100        500 U               1                                       

  36                      13          14 893                                    100        250 U               2 (0,12)                                

  49                      13          21 696                                    100        500 U               2 (0,12)                                

                                                                                                                                                       

  Li Y, 2003^[@r55]^      97          1                                         758.6      95                  720 EIU     1                           Children\
                                                                                                                                                       (average age, 9.7 years)

  105                     6           2951                                      99         720 EIU             1                                       

  99                      7           10 471                                    100        720 EIU             2 (0,6)                                 

                                                                                                                                                       

  120                     1           3631                                      97         1440 EIU            1           Adults\                     
                                                                                                                           (average age, 17.2 years)   

  119                     6           2455                                      100        1440 EIU            1                                       

                                                                                                                                                       

  Ren Y, 2003^[@r54]^     52          12                                        869        100                 500 U       2 (0,3)                     5--10

  58                      24          782                                       100        500 U               2 (0,3)                                 

  58                      36          379                                       100        500 U               2 (0,3)                                 

  55                      12          981                                       100        500 U               2 (0,6)                                 

  55                      24          667                                       100        500 U               2 (0,6)                                 

  55                      36          462                                       100        500 U               2 (0,6)                                 

                                                                                                                                                       

  Yao J, 2004^[@r56]^     73          2                                         260        95                  250 U       1                           2--3

                                                                                                                                                       

  Jia X, 2004^[@r57]^     91          1                                         14 407     100                 250 U       1                           2--15

                                                                                                                                                       

  Jiang W, 2008^[@r09]^   122         1                                         28         75                  250 U       1                           1--3

  125                     6           118                                       97         250 U               1                                       

  121                     7           3106                                      100        250 U               2 (0,6)                                 

                                                                                                                                                       

  167                     1           29                                        75         250 U               1           4--8                        

  168                     6           103                                       97         250 U               1                                       

  166                     7           3686                                      100        250 U               2 (0,6)                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Veraxim inactivated hepatitis A vaccine (Vero cells) is the first inactivated hepatitis A vaccine in the world to be based on Vero cell culture. It was licensed by the SFDA in 2009. Phase III clinical trial results showed a seroconversion rate of 98% among children with a vaccination schedule of 0 and 6 months apart (with doses of 800 ELISA units/0.5 mL/dose), and a rate of 97% among adults (with doses of 1600 ELISA units/1 mL/dose). There was no significant difference in systemic or local reaction rates between children (10.60% and 2.28%, respectively) and a control group (10.71% and 2.86%, respectively). In addition, systemic (8.80%) and local reaction rates (2.67%) in adults did not differ from those in a control group. However, postmarketing surveillance data are not available.^[@r35]^

Efficacy
--------

### Live attenuated vaccine

The protective efficacy against infection of the H2 and LA-1 vaccines exceeded 90% in community trials (Table [4](#tbl04){ref-type="table"}).^[@r36]^ In a community-based cohort study, the vaccine had 95% protective efficacy against outbreaks in a population where vaccine was used. A meta-analysis of the efficacy of live attenuated hepatitis A vaccine (H2 and LA-1), which included 13 randomized trials, showed that the protective efficacy was 96% (95% CI, 93%--98%), which is equivalent to that of international inactivated vaccines.^[@r37]^

###### Cohort studies of efficacy of hepatitis A vaccines produced in China

  -------------------------------------------------------------------------------------------------------------------------------------
  Study                    Vaccine   Recruitment:\                  Follow up:\                 Vaccine\      Follow-up\         
                                     No. of subject in each group   No. of hepatitis A cases\   efficacy, %   (years)            
                                                                    in each group                                                
  ------------------------ --------- ------------------------------ --------------------------- ------------- ------------ ----- ------
  Mao J, 1997^[@r27]^      H2        18 102 person-years            242 168 person-years        0             495          100   4.0

  Xu Z, 1998^[@r30]^       LAV-1     260 117                        235 235                     0             37           100   0.5

  Li Y, 2000^[@r58]^       LA-1      208 328                        192 448                     5             66           93    1.0

  84 412                   79 254    0                              22                          100           1.0                

  Zhang Y, 2001^[@r59]^    H2        10 459                         13 005                      1             20           94    3.5

  Zhuang F, 2001^[@r26]^   H2        745                            475                         0             11           100   10.0

  Ma J, 2002^[@r60]^       H2        1804                           1653                        1             14           94    3.5

  Gong J, 2003^[@r33]^     LA-1      3771                           3545                        2             71           97    3.0

  Luo D, 2004^[@r61]^      LA-1      15 779                         60 517                      1             38           90    5.0

  Wang X, 2000^[@r62]^     H2        21                             237                         1             119          98    1.0
  -------------------------------------------------------------------------------------------------------------------------------------

Randomized controlled studies during the period 1997 through 2003 (duration of follow up, 6 months to 10 years) found that the efficacy of live attenuated hepatitis A vaccines (H2 strain) produced in China was 95% to 100%.^[@r42]--[@r53]^ An LA-1 strain hepatitis A vaccine showed a protective efficacy of 95% to 100% after 2 years of follow up.^[@r38]^

### Inactivated hepatitis A vaccine

A non-randomized controlled trial evaluated the protective efficacy of TZ84 inactivated hepatitis A vaccine during a hepatitis A outbreak. No hepatitis A cases were detected among the 3365 students who received the vaccine, while 4 cases of hepatitis A were reported in the control group of 2527 people (protective efficacy, 100%).^[@r39]^

Postmarketing surveillance, including AEFI surveillance
-------------------------------------------------------

### Postmarketing surveillance

As of 2010, freeze-dried live attenuated hepatitis vaccine had been given to more than 80 million persons. Only 12 cases of mild reactions were reported directly to the manufacturers from 2007 through 2009, and no serious reactions were reported. In 2009, postmarketing surveillance data were reported for H2 vaccine given to 562 vaccinees in Jiangsu province: 35 (6%) cases of mild fever were reported, but no local reactions were noted.^[@r40]^ Postmarking surveillance data are not available for the LA-1 vaccine.

### AEFI surveillance

From 2005 through 2009, 80 382 AEFIs associated with any vaccine were reported to the China CDC through the national AEFI surveillance system. Of these, the most frequently reported were fever, local erythema, local swelling, and local sclerosis, which accounted for 78% of all AEFIs reported. Other AEFIs were anaphylaxis (9%) and aseptic abscess (4%). No fatal AEFIs and no clusters of AEFIs were reported. Overall, during 2005--2009, AEFIs among recipients of live attenuated hepatitis A vaccine accounted for 0.7% of all AEFIs reported in China. Analysis of AEFI rates by doses distributed suggests that the rates did not differ between inactivated vaccine (34 AEFI/million doses) and live attenuated vaccine (36 AEFI/million doses).^[@r25],[@r41]^

COMMENT
=======

Studies in China indicate that the dose of live attenuated hepatitis A vaccine should be at least 10^6.5^ CCID~50~/mL to obtain a satisfactory immune response.^[@r28]--[@r42]^ While immune responses to international inactivated vaccines lead to seroconversion in more than 95% of vaccinees at 2 weeks, Chinese live attenuated vaccines may require more time to generate antibodies.^[@r37]^ Field studies indicate that efficacy is 90% to 100%. With respect to inactivated vaccine, there was variation in the proportion of vaccinees who had seroconverted at 1 month. However, 100% of recipients seroconverted after administration of a 2-dose series.^[@r42]^

Initial Chinese trials of live attenuated and inactivated hepatitis A vaccines revealed no vaccine safety issues except for mild fever and local rash and indurations at the injection site. However, person-to-person transmission of live attenuated vaccine virus remains a safety concern because vaccine recipients excrete virus and transmit it to a high proportion of their contacts. Such human-to human transmission has the theoretical potential of vaccine virus mutation, including possible reversion to the wild type, as is seen with live attenuated poliovirus vaccine. Studies conducted so far have suggested that live hepatitis A vaccine virus has hereditary stability and that the vaccine strain is stable. No reversal to virulence has been documented. In addition, all infections with the attenuated virus have been asymptomatic and aminotransferases remained within normal ranges. However, there have been no studies of the practical consequence of horizontal transmission in the field, including outcomes of secondary infection and the consequences of circulation of attenuated virus.

We have several recommendations. First, we must further quantify the field effectiveness of Chinese hepatitis A vaccines. This will require precise coverage estimates, additional field investigations, and epidemiologic modeling. Investigation of post-exposure prophylaxis would also be of interest so that comparisons can be made with other hepatitis A vaccines. Second, the safety profile of the Chinese hepatitis A vaccine needs to be further documented. This will require analyses of AEFIs and calculation of AEFI rates by vaccine dose. Rigorous, high-quality postmarketing surveillance in selected communities, to measure and monitor safety and adverse reactions, will also be useful. Elements of particular interest are (1) identification of molecular markers of attenuation, (2) documentation of the genetic stability of these markers of attenuation after human passages, and (3) safety of orally ingested vaccine virus. Well-conducted large-scale clinical trials of efficacy and clinical safety will provide more robust documentation of the effectiveness and safety of Chinese hepatitis A vaccines. In view of the large volume of live hepatitis A vaccines used in China, and their potential usefulness outside China, carefully collected and validated data on safety and efficacy will be valuable. Such evidence will be a key component of a strategy to make the vaccines available for use internationally as part of global hepatitis A prevention efforts.^[@r53]^
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